IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)-- #Biopharmaceutical--IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy

Click to view original post